Biora Therapeutics Inc BIOR

Healthcare Biotechnology

Biora Therapeutics, Inc. is a biotechnology company, which is focused on creating smart pills designed for targeted drug delivery to the gastrointestinal (GI) tract, and systemic, needle-free delivery of biotherapeutics. The Company’s pipeline includes two therapeutic delivery platforms: NaviCap and BioJet. The NaviCap, targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract. The BioJet, systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules. It has two demonstration drug-device combination programs for the BioJet platform, BT-200 (GLP-1 receptor agonist) and BT-002 (adalimumab variant). Its other two programs include BT-600 (NaviCap + tofacitinib) and BT-001 (NaviCap + variant of adalimumab) for the treatment of ulcerative colitis.

NDAQ:BIOR - Post by User

Biora Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by AviseAnalyticson Dec 07, 2021 6:48am

355 Views

Post# 34205205

4 RISKY STOCKS TO AVOID ON DECLINING REVENUES AND DOWNGRADES

$PROG $SUNW $UPLD $PRPL

This week we bring to you four companies, namely Sunworks (NASDAQ: SUNW), Progenity Inc (NASDAQ: PROG), Upland Software Inc (NASDAQ: UPLD) and Purple Innovation Inc (NASDAQ: PRPL) that could turn out be to vulnerable investments, in view of the challenges being faced by these companies, such as loss of market share, dwindling revenues, tough competition or short seller interest.

Read on to learn more:

https://www.aviseanalytics.com/4-risky-stocks-to-avoid-on-declining-revenues-and-downgrades/

<< Previous

Bullboard Posts

Next >>

Nvidia reports record revenue in Q3